LivaNova’s Q3 financials exceed expectations, says GlobalData

Following the recent release of Q3 financial information from LivaNova;

Alexandra Murdoch, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view:

“LivaNova reported that 45% of its sales are attributed to neuromodulation and this growth may be due to the COVID-19 pandemic, and how various countries are recovering. Some US sales are driven largely by epilepsy centers getting back on track with surgeries after postponements due to the pandemic. Similarly, China, Taiwan, and the Middle East are performing more non-emergent surgeries, prompting the growth in sales.

“The other 55% of LivaNova’s sales are attributed to cardiovascular sales. Of this, the company reported strong growth in advanced circulatory support (ACS), global sales increase in oxygenator sales, and heart-lung machine (HLM) sales grew over 25% globally. Again, it is possible that some of the sales are a result of COVID-19, in part through delayed procedures, and in part due to an increased demand for products due to cardiovascular issues among COVID-19 patients.

“As people around the world continue to get vaccinated and the pandemic slowly subsides, LivaNova expects revenue to continue to increase through the end of 2021. As countries quickly try to work through their backlog of procedures, LivaNova could indeed be correct in its estimated revenue growth.”

More Media